Lv41
700 积分 2023-08-30 加入
Chronic kidney disease
2小时前
待确认
GLP-1 Receptor Agonists
11天前
已完结
Mechanistic insights make cancer cachexia a targetable syndrome
26天前
已完结
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
1个月前
已完结
Urine clusterin/apolipoprotein J is linked to tubular damage and renal outcomes in patients with type 2 diabetes mellitus
1个月前
已完结
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
1个月前
已完结
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
PROTECT Subgroup Analysis: Clinical Benefits of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with IgAN Who Have Proteinuria above and below 1 g/g
1个月前
已关闭
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
1个月前
已完结
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
1个月前
已完结
皖公网安备34019202002308
